Elan's Zonegran deal goes through
Elan has completed the sale of its North American and European interests in Zonegran to Eisai Inc. for €109m.
The pharmaceutical firm may also earn purchase payments of up to €92.24m when generic zonisamide is introduced in the US, which includes up to €21m on receiving marketing approval for Zonegran in Europe.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





